MOU with the team of Professor Choi Sung-il of Yonsei University College of Medicine, Korea Vaccine, and the team of Professor Yook Sung-soo of Chungbuk National University College of Medicine
Vaxdigm is accelerating avian influenza vaccine development through a four-party business agreement. (From right) Vaxdigm CEO Kim Sung-jae, Professor Yook Sung-soo of Chungbuk National University College of Medicine, Korea Vaccine CEO Ha Sung-bae, and Professor Choi Sung-il of Yonsei University College of Medicine.
With concerns about an avian influenza pandemic growing as the H5N1 avian influenza virus has recently spread to mammals and caused deaths even in the United States, Vaxdigm (VAXDIGM) announced that it has signed a four-party cooperation MOU with the team of Professor Choi Sung-il of Yonsei University College of Medicine, Korea Vaccine, and the team of Professor Yook Sung-soo of Chungbuk National University College of Medicine for the rapid development of an H5N1 highly pathogenic avian influenza vaccine.
This agreement is highly significant in that it strengthens domestic vaccine development capabilities by combining domestically developed platform technology with the expertise of each institution. Specifically, the four institutions will cooperate closely in vaccine technology and platform development, the production and quality verification of non-clinical and investigational medicinal products, safety, efficacy and quality evaluation in non-clinical animal models, and clinical trial approval and conduct.
Vaxdigm is a company holding patented platform technology for the rapid development of microorganism-based recombinant protein subunit vaccines, and is carrying out national projects on future pandemic response vaccine development for the Global Vaccine Technology Leading Centre and the Korea Vaccine Development Project Group under the Ministry of Health and Welfare. The team of Professor Choi Sung-il of Yonsei University College of Medicine has more than ten years of research experience in rapid vaccine development platforms, while the team of Professor Yook Sung-soo of Chungbuk National University College of Medicine will evaluate vaccine efficacy using solid infrastructure such as the ABSL3 facility of its zoonotic disease centre.
Korea Vaccine CEO Ha Sung-bae said, "Founded in 1956, Korea Vaccine has supplied high-quality human vaccines in Korea," adding, "Through this consortium we expect to be able to provide high-quality, safe vaccines not only to advanced countries but also to low- and middle-income countries where mRNA vaccine supply is difficult."
Vaxdigm CEO Kim Sung-jae said, "Recent new drug development must be carried out through collaboration among industry, academia, research institutes and hospitals in order to raise efficiency," adding, "By bringing together the expertise and capabilities of each institution, we will rapidly complete the development of a highly pathogenic avian influenza vaccine and contribute to securing Korea's vaccine sovereignty and to global health."
2025-02-04
With concerns about an avian influenza pandemic growing as the H5N1 avian influenza virus has recently spread to mammals and caused deaths even in the United States, Vaxdigm (VAXDIGM) announced that it has signed a four-party cooperation MOU with the team of Professor Choi Sung-il of Yonsei University College of Medicine, Korea Vaccine, and the team of Professor Yook Sung-soo of Chungbuk National University College of Medicine for the rapid development of an H5N1 highly pathogenic avian influenza vaccine.
This agreement is highly significant in that it strengthens domestic vaccine development capabilities by combining domestically developed platform technology with the expertise of each institution. Specifically, the four institutions will cooperate closely in vaccine technology and platform development, the production and quality verification of non-clinical and investigational medicinal products, safety, efficacy and quality evaluation in non-clinical animal models, and clinical trial approval and conduct.
Vaxdigm is a company holding patented platform technology for the rapid development of microorganism-based recombinant protein subunit vaccines, and is carrying out national projects on future pandemic response vaccine development for the Global Vaccine Technology Leading Centre and the Korea Vaccine Development Project Group under the Ministry of Health and Welfare. The team of Professor Choi Sung-il of Yonsei University College of Medicine has more than ten years of research experience in rapid vaccine development platforms, while the team of Professor Yook Sung-soo of Chungbuk National University College of Medicine will evaluate vaccine efficacy using solid infrastructure such as the ABSL3 facility of its zoonotic disease centre.
Korea Vaccine CEO Ha Sung-bae said, "Founded in 1956, Korea Vaccine has supplied high-quality human vaccines in Korea," adding, "Through this consortium we expect to be able to provide high-quality, safe vaccines not only to advanced countries but also to low- and middle-income countries where mRNA vaccine supply is difficult."
Vaxdigm CEO Kim Sung-jae said, "Recent new drug development must be carried out through collaboration among industry, academia, research institutes and hospitals in order to raise efficiency," adding, "By bringing together the expertise and capabilities of each institution, we will rapidly complete the development of a highly pathogenic avian influenza vaccine and contribute to securing Korea's vaccine sovereignty and to global health."